The DOI matches its Crossref record; 443 of the 443 references it cites were found in a registry or an index.
The hallmarks of cancer immune evasion
Open accessAbstract
According to the widely accepted "three Es" model, the host immune system eliminates malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium, preventing cancer outgrowth until neoplastic cells acquire genetic or epigenetic alterations that enable immune escape. This immunoevasive phenotype originates from various mechanisms that can be classified under a novel "three Cs" conceptual framework: (1) camouflage, which hides cancer cells from immune recognition, (2) coercion, which directly or indirectly interferes with immune effector cells, and (3) cytoprotection, which shields malignant cells from immune cytotoxicity. Blocking the ability of neoplastic cells to evade the host immune system is crucial for increasing the efficacy of modern immunotherapy and conventional therapeutic strategies that ultimately activate anticancer immunosurveillance. Here, we review key hallmarks of cancer immune evasion under the "three Cs" framework and discuss promising strategies targeting such immunoevasive mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–400 of 443
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Self-citationEnnishi, D., Takata, K., Béguelin, W., Duns, G., Mottok, A., Farinha, P., Bashashati, A., Saberi, S., Boyle, M., Meissner, B., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1090 · Cited by 318
Apoptotic Caspases Suppress Type I Interferon Production via the Cleavage of cGAS, MAVS, and IRF3
Ning, X., Wang, Y., Jing, M., Sha, M., Lv, M., Gao, P., Zhang, R., Huang, X., Feng, J.-M., & Jiang, Z. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.013 · Cited by 317
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche
Baldominos, P., Barbera-Mourelle, A., Barreiro, O., Huang, Y., Wight, A., Cho, J.-W., Zhao, X., Estivill, G., Adam, I., Sanchez, X., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.033 · Cited by 317
Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance
Zheng, X., Qian, Y., Fu, B., Jiao, D., Jiang, Y., Chen, P., Shen, Y., Zhang, H., Sun, R., Tian, Z., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0511-1 · Cited by 316
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307
Non-cell-autonomous cancer progression from chromosomal instability
Li, J., Hubisz, M. J., Earlie, E. M., Duran, M. A., Hong, C., Varela, A. A., Lettera, E., Deyell, M., Tavora, B., Havel, J. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06464-z · Cited by 307
Herbst, R. S., Majem, M., Barlesi, F., Carcereny, E., Chu, Q., Monnet, I., Sanchez-Hernandez, A., Dakhil, S., Camidge, D. R., Winzer, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00227 · Cited by 304
SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity
Guo, C., You, Z., Shi, H., Sun, Y., Du, X., Palacios, G., Guy, C., Yuan, S., Chapman, N. M., Lim, S. A., et al. (2023) · Nature · doi:10.1038/s41586-023-06299-8 · Cited by 304
Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans
Galletti, G., De Simone, G., Mazza, E. M. C., Puccio, S., Mezzanotte, C., Bi, T. M., Davydov, A. N., Metsger, M., Scamardella, E., Alvisi, G., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0791-5 · Cited by 299
Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes
Cerboni, S., Jeremiah, N., Gentili, M., Gehrmann, U., Conrad, C., Stolzenberg, M.-C., Picard, C., Neven, B., Fischer, A., Amigorena, S., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161674 · Cited by 299
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
Holder, A. M., Dedeilia, A., Sierra-Davidson, K., Cohen, S., Liu, D., Parikh, A., & Boland, G. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00705-7 · Cited by 298
Sun, J., Bird, C. H., Sutton, V., McDonald, L., Coughlin, P. B., De Jong, T. A., Trapani, J. A., & Bird, P. I. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27802 · Cited by 297
Kim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291
The autophagic network and cancer
Rybstein, M. D., Bravo-San Pedro, J. M., Kroemer, G., & Galluzzi, L. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0042-2 · Cited by 289
Self-citationOncometabolite d -2HG alters T cell metabolism to impair CD8 + T cell function
Notarangelo, G., Spinelli, J. B., Perez, E. M., Baker, G. J., Kurmi, K., Elia, I., Stopka, S. A., Baquer, G., Lin, J.-R., Golby, A. J., et al. (2022) · Science · doi:10.1126/science.abj5104 · Cited by 289
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S. J., Church, C. D., Vandeven, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 286
Kong, Y., Rose, C. M., Cass, A. A., Williams, A. G., Darwish, M., Lianoglou, S., Haverty, P. M., Tong, A.-J., Blanchette, C., Albert, M. L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13035-2 · Cited by 285
Wu, L., Jin, Y., Zhao, X., Tang, K., Zhao, Y., Tong, L., Yu, X., Xiong, K., Luo, C., Zhu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.001 · Cited by 284
Metabolic and Signaling Roles of Ketone Bodies in Health and Disease
Puchalska, P., & Crawford, P. A. (2021) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-111120-111518 · Cited by 282
l -2-Hydroxyglutarate: An Epigenetic Modifier and Putative Oncometabolite in Renal Cancer
Shim, E.-H., Livi, C. B., Rakheja, D., Tan, J., Benson, D., Parekh, V., Kho, E.-Y., Ghosh, A. P., Kirkman, R., Velu, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0696 · Cited by 280
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Morrison, L., Loibl, S., & Turner, N. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00840-4 · Cited by 280
Sattiraju, A., Kang, S., Giotti, B., Chen, Z., Marallano, V. J., Brusco, C., Ramakrishnan, A., Shen, L., Tsankov, A. M., Hambardzumyan, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.017 · Cited by 279
A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion
Dersh, D., Hollý, J., & Yewdell, J. W. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0390-6 · Cited by 278
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0106-z · Cited by 274
Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death
Hayashi, K., Nikolos, F., Lee, Y. C., Jain, A., Tsouko, E., Gao, H., Kasabyan, A., Leung, H. E., Osipov, A., Jung, S. Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19970-9 · Cited by 274
Freed-Pastor, W. A., Lambert, L. J., Ely, Z. A., Pattada, N. B., Bhutkar, A., Eng, G., Mercer, K. L., Garcia, A. P., Lin, L., Rideout, W. M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.007 · Cited by 273
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements
Zhang, S.-M., Cai, W. L., Liu, X., Thakral, D., Luo, J., Chan, L. H., McGeary, M. K., Song, E., Blenman, K. R. M., Micevic, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03994-2 · Cited by 272
Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity
Vignali, P. D. A., DePeaux, K., Watson, M. J., Ye, C., Ford, B. R., Lontos, K., McGaa, N. K., Scharping, N. E., Menk, A. V., Robson, S. C., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01379-9 · Cited by 269
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold
Vredevoogd, D. W., Kuilman, T., Ligtenberg, M. A., Boshuizen, J., Stecker, K. E., de Bruijn, B., Krijgsman, O., Huang, X., Kenski, J. C. N., Lacroix, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.014 · Cited by 259
Mitochondrial permeabilization engages NF-κB-dependent anti-tumour activity under caspase deficiency
Giampazolias, E., Zunino, B., Dhayade, S., Bock, F., Cloix, C., Cao, K., Roca, A., Lopez, J., Ichim, G., Proïcs, E., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3596 · Cited by 258
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
Jiang, N., Xie, B., Xiao, W., Fan, M., Xu, S., Duan, Y., Hamsafar, Y., Evans, A. C., Huang, J., Zhou, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29137-3 · Cited by 258
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 257
Devalaraja, S., To, T. K. J., Folkert, I. W., Natesan, R., Alam, M. Z., Li, M., Tada, Y., Budagyan, K., Dang, M. T., Zhai, L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.042 · Cited by 257
Noman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256
Sublethal cytochrome c release generates drug-tolerant persister cells
Kalkavan, H., Chen, M. J., Crawford, J. C., Quarato, G., Fitzgerald, P., Tait, S. W. G., Goding, C. R., & Green, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.07.025 · Cited by 255
Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 251
Cytosolic DNA Sensing in Organismal Tumor Control
Vanpouille-Box, C., Demaria, S., Formenti, S. C., & Galluzzi, L. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.013 · Cited by 250
Self-citationSTING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
Hu, J., Sánchez-Rivera, F. J., Wang, Z., Johnson, G. N., Ho, Y.-J., Ganesh, K., Umeda, S., Gan, S., Mujal, A. M., Delconte, R. B., et al. (2023) · Nature · doi:10.1038/s41586-023-05880-5 · Cited by 247
Quiescent tissue stem cells evade immune surveillance
Agudo, J., Park, E. S., Rose, S. A., Alibo, E., Sweeney, R., Dhainaut, M., Kobayashi, K. S., Sachidanandam, R., Baccarini, A., Merad, M., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.001 · Cited by 244
ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
Hu, M., Zhou, M., Bao, X., Pan, D., Jiao, M., Liu, X., Li, F., & Li, C.-Y. (2021) · Journal of Clinical Investigation · doi:10.1172/jci139333 · Cited by 244
Structural basis for the inhibition of cGAS by nucleosomes
Kujirai, T., Zierhut, C., Takizawa, Y., Kim, R., Negishi, L., Uruma, N., Hirai, S., Funabiki, H., & Kurumizaka, H. (2020) · Science · doi:10.1126/science.abd0237 · Cited by 243
Gao, X., Wang, X., Yang, Q., Zhao, X., Wen, W., Li, G., Lu, J., Qin, W., Qi, Y., Xie, F., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401344 · Cited by 242
Su, W., Han, H. H., Wang, Y., Zhang, B., Zhou, B., Cheng, Y., Rumandla, A., Gurrapu, S., Chakraborty, G., Su, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.009 · Cited by 242
Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma
Hung, M. H., Lee, J. S., Ma, C., Diggs, L. P., Heinrich, S., Chang, C. W., Ma, L., Forgues, M., Budhu, A., Chaisaingmongkol, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21804-1 · Cited by 238
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
Koikawa, K., Kibe, S., Suizu, F., Sekino, N., Kim, N., Manz, T. D., Pinch, B. J., Akshinthala, D., Verma, A., Gaglia, G., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.020 · Cited by 233
Lysine catabolism reprograms tumour immunity through histone crotonylation
Yuan, H., Wu, X., Wu, Q., Chatoff, A., Megill, E., Gao, J., Huang, T., Duan, T., Yang, K., Jin, C., et al. (2023) · Nature · doi:10.1038/s41586-023-06061-0 · Cited by 233
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity
Kim, H., Kim, H., Feng, Y., Li, Y., Tamiya, H., Tocci, S., & Ronai, Z. A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz5683 · Cited by 232
ATP and cancer immunosurveillance
Kepp, O., Bezu, L., Yamazaki, T., Di Virgilio, F., Smyth, M. J., Kroemer, G., & Galluzzi, L. (2021) · The EMBO Journal · doi:10.15252/embj.2021108130 · Cited by 229
Self-citationADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis
Liu, H., Kuang, X., Zhang, Y., Ye, Y., Li, J., Liang, L., Xie, Z., Weng, L., Guo, J., Li, H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.006 · Cited by 227
PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function
Morotti, M., Grimm, A. J., Hope, H. C., Arnaud, M., Desbuisson, M., Rayroux, N., Barras, D., Masid, M., Murgues, B., Chap, B. S., et al. (2024) · Nature · doi:10.1038/s41586-024-07352-w · Cited by 221
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer
Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01315-x · Cited by 218
Integrin αvβ6–TGFβ–SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer
Bagati, A., Kumar, S., Jiang, P., Pyrdol, J., Zou, A. E., Godicelj, A., Mathewson, N. D., Cartwright, A. N. R., Cejas, P., Brown, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.001 · Cited by 215
Tumour heterogeneity and the evolutionary trade-offs of cancer
Hausser, J., & Alon, U. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0241-6 · Cited by 214
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Self-citationByun, J.-K., Park, M., Lee, S., Yun, J. W., Lee, J., Kim, J. S., Cho, S. J., Jeon, H.-J., Lee, I.-K., Choi, Y.-K., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.015 · Cited by 208
USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer
Shi, D., Wu, X., Jian, Y., Wang, J., Huang, C., Mo, S., Li, Y., Li, F., Zhang, C., Zhang, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33285-x · Cited by 207
Liu, Q., Zhang, J., Guo, C., Wang, M., Wang, C., Yan, Y., Sun, L., Wang, D., Zhang, L., Yu, H., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.004 · Cited by 207
PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells
Lacher, S. B., Dörr, J., de Almeida, G. P., Hönninger, J., Bayerl, F., Hirschberger, A., Pedde, A.-M., Meiser, P., Ramsauer, L., Rudolph, T. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07254-x · Cited by 207
A membrane-associated MHC-I inhibitory axis for cancer immune evasion
Chen, X., Lu, Q., Zhou, H., Liu, J., Nadorp, B., Lasry, A., Sun, Z., Lai, B., Rona, G., Zhang, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.016 · Cited by 205
ER-directed TREX1 limits cGAS activation at micronuclei
Mohr, L., Toufektchan, E., von Morgen, P., Chu, K., Kapoor, A., & Maciejowski, J. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.037 · Cited by 204
Bayerl, F., Meiser, P., Donakonda, S., Hirschberger, A., Lacher, S. B., Pedde, A.-M., Hermann, C. D., Elewaut, A., Knolle, M., Ramsauer, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.05.011 · Cited by 203
Meiser, P., Knolle, M. A., Hirschberger, A., de Almeida, G. P., Bayerl, F., Lacher, S., Pedde, A.-M., Flommersfeld, S., Hönninger, J., Stark, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.008 · Cited by 203
Genomic–transcriptomic evolution in lung cancer and metastasis
Martínez-Ruiz, C., Black, J. R. M., Puttick, C., Hill, M. S., Demeulemeester, J., Larose Cadieux, E., Thol, K., Jones, T. P., Veeriah, S., Naceur-Lombardelli, C., et al. (2023) · Nature · doi:10.1038/s41586-023-05706-4 · Cited by 201
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma
Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199
Fucikova, J., Becht, E., Iribarren, K., Goc, J., Remark, R., Damotte, D., Alifano, M., Devi, P., Biton, J., Germain, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1142 · Cited by 199
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment
Dillon, M. T., Bergerhoff, K. F., Pedersen, M., Whittock, H., Crespo-Rodriguez, E., Patin, E. C., Pearson, A., Smith, H. G., Paget, J. T. E., Patel, R. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1821 · Cited by 199
Y chromosome loss in cancer drives growth by evasion of adaptive immunity
Abdel-Hafiz, H. A., Schafer, J. M., Chen, X., Xiao, T., Gauntner, T. D., Li, Z., & Theodorescu, D. (2023) · Nature · doi:10.1038/s41586-023-06234-x · Cited by 197
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma
Qian, Y., Galan-Cobo, A., Guijarro, I., Dang, M., Molkentine, D., Poteete, A., Zhang, F., Wang, Q., Wang, J., Parra, E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.015 · Cited by 193
Leone, R. D., Sun, I.-M., Oh, M.-H., Sun, I.-H., Wen, J., Englert, J., & Powell, J. D. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2186-0 · Cited by 190
TGF-β suppresses type 2 immunity to cancer
Liu, M., Kuo, F., Capistrano, K. J., Kang, D., Nixon, B. G., Shi, W., Chou, C., Do, M. H., Stamatiades, E. G., Gao, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2836-1 · Cited by 187
Self-citationTrial watch: IDO inhibitors in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1777625 · Cited by 187
Self-citationThe NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells
Sen Santara, S., Lee, D.-J., Crespo, Â., Hu, J. J., Walker, C., Ma, X., Zhang, Y., Chowdhury, S., Meza-Sosa, K. F., Lewandrowski, M., et al. (2023) · Nature · doi:10.1038/s41586-023-05912-0 · Cited by 187
Dovedi, S. J., Elder, M. J., Yang, C., Sitnikova, S. I., Irving, L., Hansen, A., Hair, J., Jones, D. C., Hasani, S., Wang, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1445 · Cited by 186
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
Self-citationCancer stem cell mimicry for immune evasion and therapeutic resistance
Saw, P. E., Liu, Q., Wong, P., & Song, E. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.06.003 · Cited by 182
Cheng, J., Yan, J., Liu, Y., Shi, J., Wang, H., Zhou, H., Zhou, Y., Zhang, T., Zhao, L., Meng, X., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.04.017 · Cited by 177
Immunosurveillance in clinical cancer management
Kroemer, G., Chan, T. A.-T., Eggermont, A. M. M., & Galluzzi, L. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21818 · Cited by 175
Self-citationMechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 175
Targeting TBK1 to overcome resistance to cancer immunotherapy
Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05704-6 · Cited by 174
Mandula, J. K., Chang, S., Mohamed, E., Jimenez, R., Sierra-Mondragon, R. A., Chang, D. C., Obermayer, A. N., Moran-Segura, C. M., Das, S., Vazquez-Martinez, J. A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.016 · Cited by 173
Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz6804 · Cited by 172
Choueiri, T. K., Eto, M., Motzer, R., De Giorgi, U., Buchler, T., Basappa, N. S., Méndez-Vidal, M. J., Tjulandin, S., Hoon Park, S., Melichar, B., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00049-9 · Cited by 172
Taifour, T., Attalla, S. S., Zuo, D., Gu, Y., Sanguin-Gendreau, V., Proud, H., Solymoss, E., Bui, T., Kuasne, H., Papavasiliou, V., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.11.002 · Cited by 171
Zhou, X., Singh, M., Sanz Santos, G., Guerlavais, V., Carvajal, L. A., Aivado, M., Zhan, Y., Oliveira, M. M. S., Westerberg, L. S., Annis, D. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1741 · Cited by 169
Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., & Childs, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1108 · Cited by 166
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Riaz, N., Havel, J. J., Kendall, S. M., Makarov, V., Walsh, L. A., Desrichard, A., Weinhold, N., & Chan, T. A.-T. (2016) · Nature Genetics · doi:10.1038/ng.3677 · Cited by 166
Self-citationMRE11 liberates cGAS from nucleosome sequestration during tumorigenesis
Cho, M.-G., Kumar, R. J., Lin, C.-C., Boyer, J. A., Shahir, J. A., Fagan‐Solis, K. D., Simpson, D. A., Fan, C., Foster, C. E., Goddard, A. M., et al. (2024) · Nature · doi:10.1038/s41586-023-06889-6 · Cited by 165
Li, Z.-L., Zhang, H.-L., Huang, Y., Huang, J.-H., Sun, P., Zhou, N.-N., Chen, Y.-H., Mai, J., Wang, Y., Yu, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17395-y · Cited by 163
Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling
Han, C., Liu, Z., Zhang, Y., Shen, A., Dong, C., Zhang, A., Moore, C., Ren, Z., Lu, C., Cao, X., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0641-5 · Cited by 162
Fatty Acid Transport and Signaling: Mechanisms and Physiological Implications
Samovski, D., Jácome-Sosa, M., & Abumrad, N. A. (2022) · Annual Review of Physiology · doi:10.1146/annurev-physiol-032122-030352 · Cited by 162
Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance
Rubio‐Patiño, C., Bossowski, J. P., Donatis, G. M. D., Mondragón, L., Villa, E., Aira, L. E., Chiche, J., Mhaidly, R., Lebeaupin, C., Marchetti, S., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.009 · Cited by 161
Jia, L., Zhang, W., & Wang, C. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.06.022 · Cited by 161
The status of tumor mutational burden and immunotherapy
Anagnostou, V., Bardelli, A., Chan, T. A.-T., & Turajlic, S. (2022) · Nature Cancer · doi:10.1038/s43018-022-00382-1 · Cited by 161
Self-citationSong, X., Zhou, Z., Li, H., Xue, Y., Lu, X., Bahar, İ., Kepp, O., Hung, M., Kroemer, G., & Wan, Y. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0402 · Cited by 160
MCT4 blockade increases the efficacy of immune checkpoint blockade
Babl, N., Decking, S.-M., Voll, F., Althammer, M., Sala-Hojman, A., Ferretti, R., Korf, C., Schmidl, C., Schmidleithner, L., Nerb, B., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007349 · Cited by 160
Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer
Fucikova, J., Moserova, I., Urbanova, L., Bezu, L., Kepp, O., Cremer, I., Salek, C., Strnad, P., Kroemer, G., Galluzzi, L., et al. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00402 · Cited by 159
Self-citationJiang, L., Fang, X., Wang, H., Li, D., & Wang, X. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02927 · Cited by 159
Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance
Lin, H., Kryczek, I., Li, S., Green, M. D., Ali, A., Hamasha, R., Wei, S., Vatan, L., Szeliga, W., Grove, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.023 · Cited by 159
Signaling and Polarized Communication Across the T Cell Immunological Synapse
Dustin, M. L., & Choudhuri, K. (2016) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100814-125330 · Cited by 158
Caspase-7 activates ASM to repair gasdermin and perforin pores
Nozaki, K., Maltez, V. I., Rayamajhi, M., Tubbs, A. L., Mitchell, J. E., Lacey, C. A., Harvest, C. K., Li, L., Nash, W., Larson, H. N., et al. (2022) · Nature · doi:10.1038/s41586-022-04825-8 · Cited by 158
Bladergroen, B. A., Strik, M. C. M., Bovenschen, N., van Berkum, O., Scheffer, G. L., Meijer, C. J. L. M., Hack, C. E., & Kummer, J. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3218 · Cited by 157
The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation
Martin, T. D., Patel, R. S., Cook, D. R., Choi, M. Y., Patil, A., Liang, A. C. T., Li, M. Z., Haigis, K. M., & Elledge, S. J. (2021) · Science · doi:10.1126/science.abg5784 · Cited by 156
Ritter, C., Fan, K., Paschen, A., Hadrup, S. R., Ferrone, S., Nghiem, P., Ugurel, S., Schrama, D., & Becker, J. C. (2017) · Scientific Reports · doi:10.1038/s41598-017-02608-0 · Cited by 155
NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer
Salomé, B., Sfakianos, J. P., Ranti, D. L., Daza, J., Bieber, C., Charap, A., Hammer, C., Banchereau, R., Farkas, A. M., Ruan, D. F., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.005 · Cited by 154
Bianchi, A., Silva, I. D. C., Deshpande, N., Singh, S. P., Mehra, S., Garrido, V. T., Guo, X., Nivelo, L. A., Kolonias, D. S., Saigh, S. J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1046 · Cited by 154
SnapShot: CGAS-STING Signaling
Galluzzi, L., Vanpouille‐Box, C., Bakhoum, S. F. W., & Demaria, S. (2018) · Cell · doi:10.1016/j.cell.2018.03.015 · Cited by 152
Self-citationESCRT-mediated membrane repair protects tumor-derived cells against T cell attack
Ritter, A. T., Shtengel, G. E., Xu, C. S., Weigel, A. V., Hoffman, D. P., Freeman, M., Iyer, N., Alivodej, N., Ackerman, D., Voskoboinik, I., et al. (2022) · Science · doi:10.1126/science.abl3855 · Cited by 152
CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection
Wennerberg, E., Spada, S., Rudqvist, N.-P., Lhuillier, C., Gruber, S., Chen, Q., Zhang, F., Zhou, X. K., Gross, S. S., Formenti, S. C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0449 · Cited by 151
Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses
Galluzzi, L., Vacchelli, E., Michels, J., Garcia, P., Kepp, O., Senovilla, L., Vitale, I., & Kroemer, G. (2013) · Oncogene · doi:10.1038/onc.2012.623 · Cited by 150
Self-citationAbsi, A. A., Wurzer, H., Guérin, C. L., Hoffmann, C., Moreau, F., Mao, X., Brown-Clay, J. D., Petrolli, R., Casellas, C. P., Dieterle, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0441 · Cited by 150
CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy
Ma, Y., Mattarollo, S. R., Adjemian, S., Yang, H., Aymeric, L., Hannani, D., Catani, J. P. P., Duret, H., Teng, M. W. L., Kepp, O., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1265 · Cited by 149
Self-citationThe expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 149
PI3Kβ controls immune evasion in PTEN-deficient breast tumours
Bergholz, J. S., Wang, Q., Wang, Q., Ramseier, M. L., Prakadan, S. M., Wang, W., Fang, R., Kabraji, S. K., Zhou, Q., Gray, G. K., et al. (2023) · Nature · doi:10.1038/s41586-023-05940-w · Cited by 149
Rodriguez-Ruiz, M. E., Buqué, A., Hensler, M., Chen, J., Bloy, N., Petroni, G., Sato, A., Yamazaki, T., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655964 · Cited by 147
Self-citationVenkatesan, S., Angelova, M., Puttick, C., Zhai, H.-R., Caswell, D. R., Lu, W.-T., Dietzen, M., Galanos, P., Evangelou, K., Bellelli, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0725 · Cited by 145
Tumor hypoxia represses γδ T cell-mediated antitumor immunity against brain tumors
Park, J. H., Kim, H.-J., Kim, C. W., Kim, H. C., Jung, Y., Lee, H., Lee, Y., Ju, Y. S., Oh, J. E., Park, S., et al. (2021) · Nature Immunology · doi:10.1038/s41590-020-00860-7 · Cited by 143
Lakhani, N. J., Chow, L. Q. M., Gainor, J. F., LoRusso, P. M., Lee, K.-W., Chung, H. C., Lee, J., Bang, Y.-J., Hodi, F. S., Kim, W. S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00584-2 · Cited by 143
Miller, K. D., O’Connor, S., Pniewski, K. A., Kannan, T., Acosta, R., Mirji, G., Papp, S. B., Hulse, M., Mukha, D., Hlavaty, S. I., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00636-6 · Cited by 142
Cell Softness Prevents Cytolytic T Cell Killing of Tumor-Repopulating Cells
Liu, Y., Zhang, T., Zhou, N., Fiskesund, R., Liang, X., Chen, J., Lv, J., Xie, J., Ma, J., Zhang, H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-20-2569 · Cited by 141
Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity
Giampazolias, E., Schulz, O., Lim, K. H. J., Rogers, N. C., Chakravarty, P., Srinivasan, N., Gordon, O., Cardoso, A., Buck, M. D., Poirier, E. Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.021 · Cited by 141
Klement, J. D., Redd, P. S., Lu, C., Merting, A. D., Poschel, D. B., Yang, D., Savage, N. M., Zhou, G., Munn, D. H., Fallon, P. G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.005 · Cited by 140
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
Self-citationImmunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Buqué, A., Bloy, N., Perez-Lanzón, M., Iribarren, K., Humeau, J., Pol, J. G., Levesque, S., Mondragon, L., Yamazaki, T., Sato, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17644-0 · Cited by 138
Self-citationeIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Suresh, S., Chen, B., Zhu, J., Golden, R. J., Lu, C., Evers, B. M., Novaresi, N., Smith, B., Zhan, X., Schmid, V., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0056-0 · Cited by 138
Fucikova, J., Truxova, I., Hensler, M., Becht, E., Kasikova, L., Moserova, I., Vosahlikova, S., Klouckova, J., Church, S. E., Cremer, I., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731737 · Cited by 135
Self-citationWémeau, M., Kepp, O., Tesnière, A., Panaretakis, T., Flament, C., de Botton, S., Zitvogel, L., Kroemer, G., & Chaput, N. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.82 · Cited by 135
ENPP1’s regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling
Carozza, J. A., Cordova, A. F., Brown, J. A., AlSaif, Y., Böhnert, V., Cao, X., Mardjuki, R. E., Skariah, G. M., Fernández, D., & Li, L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2119189119 · Cited by 135
Manipulating mitochondrial electron flow enhances tumor immunogenicity
Mangalhara, K. C., Varanasi, S. K., Johnson, M. A., Burns, M. J., Rojas, G. R., Esparza‐Moltó, P. B., Sainz, A. G., Tadepalle, N., Abbott, K. L., Mendiratta, G., et al. (2023) · Science · doi:10.1126/science.abq1053 · Cited by 135
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Chew, G.-L., Campbell, A. E., Neef, E. D., Sutliff, N. A., Shadle, S. C., Tapscott, S. J., & Bradley, R. K. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.011 · Cited by 134
Immunosuppression by Mutated Calreticulin Released from Malignant Cells
Liu, P., Zhao, L., Loos, F., Marty, C., Xie, W., Martins, I., Lachkar, S., Qu, B., Waeckel-Énée, E., Plo, I., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.004 · Cited by 130
Wang, Z., Li, B., Li, S., Lin, W., Wang, Z., Wang, S., Chen, W., Shi, W., Chen, T., Zhou, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34064-4 · Cited by 130
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B
Musella, M., Guarracino, A., Manduca, N., Galassi, C., Ruggiero, E., Potenza, A., Maccafeo, E., Manic, G., Mattiello, L., Rehim, S. S. A., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01290-3 · Cited by 129
Self-citationBiochemistry, Cell Biology, and Pathophysiology of the Innate Immune cGAS–cGAMP–STING Pathway
Ritchie, C., Carozza, J. A., & Li, L. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-040320-101629 · Cited by 128
Wang, G., Xu, J., Zhao, J., Yin, W., Liu, D., Chen, W., & Hou, X. S. (2020) · Nature Communications · doi:10.1038/s41467-019-14046-9 · Cited by 127
Tumors evade immune cytotoxicity by altering the surface topology of NK cells
Zheng, X., Hou, Z., Qian, Y., Zhang, Y., Cui, Q., Wang, X., Shen, Y., Liu, Z., Zhou, Y., Fu, B., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01462-9 · Cited by 127
The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING–IFN-β pathway
Takahashi, M., Lio, C. J., Campeau, A., Steger, M., Ay, F., Mann, M., Gonzalez, D. J., Jain, M., & Sharma, S. (2021) · Nature Immunology · doi:10.1038/s41590-021-00896-3 · Cited by 126
Montrose, D. C., Saha, S., Foronda, M., McNally, E. M., Chen, J. B., Zhou, X. K., Ha, T., Krumsiek, J., Büyüközkan, M., Verma, A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1541 · Cited by 124
Self-citationThe DNA Damage Response and Inflammation in Cancer
Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 123
Self-citationHow protons pave the way to aggressive cancers
Swietach, P., Boedtkjer, E., & Pedersen, S. F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00628-9 · Cited by 123
SOX17 enables immune evasion of early colorectal adenomas and cancers
Goto, N., Westcott, P. M. K., Goto, S., Imada, S., Taylor, M. S., Eng, G. M., Braverman, J., Deshpande, V., Jacks, T., Agudo, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07135-3 · Cited by 123
Activation of human endogenous retroviruses and its physiological consequences
Dopkins, N., & Nixon, D. F. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00674-z · Cited by 122
Genetic immune escape landscape in primary and metastatic cancer
Martínez-Jiménez, F., Priestley, P., Shale, C., Baber, J., Rozemuller, E. H., & Cuppen, E. P. J. G. (2023) · Nature Genetics · doi:10.1038/s41588-023-01367-1 · Cited by 120
TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Tani, T., Mathsyaraja, H., Campisi, M., Li, Z., Haratani, K., Fahey, C. G., Ota, K., Mahadevan, N. R., Shi, Y., Saito, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0700 · Cited by 119
Murayama, T., Nakayama, J., Jiang, X., Miyata, K., Morris, A. D., Cai, K. Q., Prasad, R. M., Ma, X., Efimov, A., Belani, N., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0486 · Cited by 118
Li, Z., Ma, R., Tang, H., Guo, J., Shah, Z., Zhang, J., Liu, N., Cao, S., Marcucci, G., Artis, D., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.015 · Cited by 118
Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117
Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy
Jiang, L., Wang, Y., Zhao, J., Uehara, M., Hou, Q., Kasinath, V., Ichimura, T., Banouni, N., Dai, L., Li, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.045 · Cited by 117
Wei, R., Zhou, Y., Li, C., Rychahou, P. G., Zhang, S., Titlow, W. B., Bauman, G., Wu, Y., Liu, J., Wang, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2778 · Cited by 116
Leuzzi, G., Vasciaveo, A., Taglialatela, A., Chen, X., Firestone, T. M., Hickman, A. R., Mao, W., Thakar, T., Vaitsiankova, A., Huang, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.008 · Cited by 116
Cellular cytotoxicity is a form of immunogenic cell death
Minute, L., Teijeira, Á., Sánchez-Paulete, A. R., Ochoa, M. C., Álvarez, M., Otano, I., Etxeberría, I., Bolaños, E., Azpilikueta, A., Garasa, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000325 · Cited by 115
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity
Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., Walsh, Z. H., Kyrysyuk, O., Amin, A. D., Caprio, L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.014 · Cited by 115
Hou, Y., Wang, Z., Liu, P., Wei, X., Zhang, Z., Fan, S., Zhang, L., Han, F., Song, Y., Chu, L., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.10.001 · Cited by 115
Marzio, A., Kurz, E., Sahni, J. M., Feo, G. D., Puccini, J., Jiang, S., Hirsch, C. A., Arbini, A., Wu, W., Pass, H. I., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.005 · Cited by 114
Tacchio, M. D., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0865 · Cited by 113
Takaki, T., Millar, R., Hiley, C. T., & Boulton, S. J. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.04.017 · Cited by 107
Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
Bruchard, M., Geindreau, M., Perrichet, A., Truntzer, C., Ballot, E., Boidot, R., Racoeur, C., Barsac, E., Chalmin, F., Hibos, C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-021-01120-y · Cited by 106
Goddard, E. T., Linde, M. H., Srivastava, S., Klug, G., Shabaneh, T. B., Iannone, S., Grzelak, C. A., Marsh, S. A., Riggio, A. I., Shor, R. E., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.011 · Cited by 106
ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer
Wang, S., Böhnert, V., Joseph, A. J., Sudaryo, V., Skariah, G. M., Swinderman, J. T., Yu, F. B., Subramanyam, V., Wolf, D. M., Lyu, X., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2313693120 · Cited by 105
Zhang, W., Liu, W., Jia, L., Chen, D., Chang, I., Lake, M. P., Bentolila, L. A., & Wang, C. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.038 · Cited by 104
Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1026 · Cited by 104
Gupta, V. K., Sharma, N., Durden, B. C., Garrido, V. T., Kesh, K., Edwards, D., Wang, D., Myer, C., Mateo-Victoriano, B., Kollala, S. S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2562 · Cited by 100
Cristini, A., Tellier, M., Constantinescu, F., Accalai, C., Albulescu, L.-O., Heiringhoff, R. S., Béry, N., Sordet, O., Murphy, S., & Gromak, N. (2022) · Nature Communications · doi:10.1038/s41467-022-30604-0 · Cited by 99
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
Zeng, Q., Saghafinia, S., Chryplewicz, A., Fournier, N., Christe, L., Xie, Y., Guillot, J., Yucel, S., Li, P., Galván, J. A., et al. (2022) · Science · doi:10.1126/science.abl7207 · Cited by 98
Extracorporeal photochemotherapy induces bona fide immunogenic cell death
Tatsuno, K., Yamazaki, T., Hanlon, D. J., Han, P., Robinson, E., Sobolev, O., Yurter, A., Rivera-Molina, F. E., Arshad, N., Edelson, R. L., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1819-3 · Cited by 97
Self-citationAutoimmunity gene IRGM suppresses cGAS‐STING and RIG‐I‐MAVS signaling to control interferon response
Jena, K. K., Mehto, S., Nath, P., Chauhan, N. R., Sahu, R., Dhar, K., Das, S. K., Kolapalli, S. P., Murmu, K. C., Jain, A., et al. (2020) · EMBO Reports · doi:10.15252/embr.202050051 · Cited by 96
Epigenetic changes in tumor Fas levels determine immune escape and response to therapy
Maecker, H. L., Yun, Z., Maecker, H. T., & Giaccia, A. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00095-8 · Cited by 93
Roulston, A., Zimmermann, M., Papp, R., Skeldon, A. M., Pellerin, C., Dumas-Bérube, É., Dumais, V., Dorich, S., Fader, L. D., Fournier, S., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0615 · Cited by 93
Zhong, J., Yang, X., Chen, J., He, K., Gao, X., Wu, X., Zhang, M., Zhou, H., Xiao, F., An, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32311-2 · Cited by 93
Jaime‐Sánchez, P., Uranga-Murillo, I., Aguiló, N., Khouili, S. C., Arias, M. A., Sancho, D., & Pardo, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000528 · Cited by 92
Arf1 coordinates fatty acid metabolism and mitochondrial homeostasis
Enkler, L., Szentgyörgyi, V., Pennauer, M., Prescianotto‐Baschong, C., Riezman, I., Więsyk, A., Avraham, R. E., Spiess, M., Zalckvar, E., Kucharczyk, R., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01180-2 · Cited by 86
Murphy, S., Rahmy, S., Gan, D., Liu, G., Zhu, Y., Manyak, M., Duong, L., He, J., Schofield, J. H., Schafer, Z. T., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2742 · Cited by 85
Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002722 · Cited by 83
Yokoyama, Y., Estok, T. M., & Wild, R. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0282 · Cited by 80
Khazen, R., Müller, S., Gaudenzio, N., Espinosa, É., Puisségur, M.-P., & Valitutti, S. (2016) · Nature Communications · doi:10.1038/ncomms10823 · Cited by 79
López, E., Karattil, R., Nannini, F., Cheung, G. W.-K., Denzler, L., Gálvez‐Cancino, F., Quezada, S. A., & Pulè, M. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006287 · Cited by 78
Darvin, P., Nair, V. S., & Elkord, E. (2019) · Journal of Oncology · doi:10.1155/2019/3958908 · Cited by 77
Kesarwani, P., Kant, S., Zhao, Y., Prabhu, A. H., Buelow, K. L., Miller, C. R., & Chinnaiyan, P. (2023) · Nature Communications · doi:10.1038/s41467-023-37170-z · Cited by 77
Preillon, J., Cuende, J., Rabolli, V., Garnero, L., Mercier, M., Wald, N., Pappalardo, A., Denies, S., Jamart, D., Michaux, A.-C., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0464 · Cited by 75
CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity
Tang, Z.-H., Zhong, M., Qian, J., Galindo, C. C., Davidson, D., Li, J., Zhao, Y., Hui, E., & Veillette, A. (2023) · Nature Immunology · doi:10.1038/s41590-023-01671-2 · Cited by 73
Saha, S., Ghosh, M., Li, J., Wen, A., Galluzzi, L., Martinez, L. A., & Montrose, D. C. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-1788 · Cited by 72
Self-citationBailey, C. P., Figueroa, M., Gangadharan, A., Yang, Y., Romero, M. M., Kennis, B. A., Yadavilli, S., Henry, V. K., Collier, T. L., Monje, M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa058 · Cited by 70
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer
Chae, C.-S., Sandoval, T. A., Hwang, S., Park, E. S., Giovanelli, P., Awasthi, D., Salvagno, C., Emmanuelli, A., Tan, C., Chaudhary, V., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1181 · Cited by 70
Lai, Q., Wang, H., Li, A., Xu, Y., Tang, L., Chen, Q., Zhang, C., Gao, Y., Song, J., & Du, Z. (2018) · Oncogene · doi:10.1038/s41388-018-0125-3 · Cited by 69
Suppressive effects of tumor cell-derived 5′-deoxy-5′-methylthioadenosine on human T cells
Henrich, F. C., Singer, K., Poller, K., Bernhardt, L., Strobl, C. D., Limm, K., Ritter, A. P., Gottfried, E., Völkl, S., Jacobs, B., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1184802 · Cited by 69
Vitamin B6 Competition in the Tumor Microenvironment Hampers Antitumor Functions of NK Cells
He, C., Wang, D., Shukla, S. K., Hu, T., Thakur, R. K., Fu, X., King, R. J., Kollala, S. S., Attri, K. S., Murthy, D., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0334 · Cited by 69
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas
Li, Y., Goldberg, E. M., Chen, X., Xu, X., McGuire, J. T., Leuzzi, G., Karagiannis, D., Tate, T., Farhangdoost, N., Horth, C., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.007 · Cited by 68
Tang, T., Huang, X., Lu, M., Zhang, G., Han, X., & Liang, T. (2023) · Nature Communications · doi:10.1038/s41467-023-38578-3 · Cited by 68
Cunniff, E. C., Sato, Y., Mai, D., Appleman, V. A., Iwasaki, S., Kolev, V. N., Matsuda, A., Shi, J. Q., Mochizuki, M., Yoshikawa, M., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0161 · Cited by 67
Receptor-interacting Protein Kinase 2 Is an Immunotherapy Target in Pancreatic Cancer
Sang, W., Zhou, Y., Chen, H., Yu, C., Dai, L., Liu, Z., Chen, L., Fang, Y., Ma, P., Wu, X., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0584 · Cited by 67
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β
Olivera, I., Pamplona, R. S., Bolaños, E., Rodríguez, I., Etxeberría, I., Cirella, A., Egea, J., Garasa, S., Miguéliz, I., Eguren‐Santamaría, I., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1115 · Cited by 66
Lei, X., Lin, H., Wang, J., Ou, Z., Ruan, Y., Sadagopan, A., Chen, W., Xie, S., Chen, B., Li, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31417-x · Cited by 66
Carnosine regulation of intracellular pH homeostasis promotes lysosome-dependent tumor immunoevasion
Yan, R., Zhang, P., Shen, S., Zeng, Y., Wang, T., Chen, Z., Ma, W., Feng, J., Suo, C., Zhang, T., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01719-3 · Cited by 66
Activin A Promotes Regulatory T-cell–Mediated Immunosuppression in Irradiated Breast Cancer
Martino, M. D., Daviaud, C., Diamond, J. M., Kraynak, J., Alard, A., Formenti, S. C., Miller, L. D., Demaria, S., & Vanpouille‐Box, C. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0305 · Cited by 65
Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC -Mutated Colorectal Cancer
Lee, R., Li, J., Li, J., Wu, C., Jiang, S., Hsu, W.-H., Chakravarti, D., Chen, P., LaBella, K. A., Li, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0680 · Cited by 65
Trajectory of immune evasion and cancer progression in hepatocellular carcinoma
Nguyen, P. H. D., Wasser, M., Tan, C. T., Lim, C. J., Lai, H. L. H., Seow, J. J. W., DasGupta, R., Phua, C. Z. J., Ma, S., Yang, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29122-w · Cited by 64
Gambacorta, V., Beretta, S., Ciccimarra, M., Zito, L., Giannetti, K., Andrisani, A., Gnani, D., Zanotti, L., Oliveira, G., Carrabba, M. G., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0980 · Cited by 63
Uslu, U., Sun, L., Castelli, S., Finck, A., Assenmacher, C., Young, R. M., Chen, Z. J., & June, C. H. (2024) · Nature Communications · doi:10.1038/s41467-024-47692-9 · Cited by 62
Research works printed but not linked: 4
- Clement, 2021, 3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine, Nat. Commun., 12, 4447, 10.1038/s41467-021-24785-3 · doi:10.1038/s41467-021-24785-3
- Sun, 2024, A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors, J. Clin. Oncol., 42, e14504, 10.1200/JCO.2024.42.16_suppl.e14504 · doi:10.1200/jco.2024.42.16_suppl.e14504
- Claff, 2023, Crystal structure of adenosine A(2A) receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction, Commun. Chem., 6, 106, 10.1038/s42004-023-00894-6 · doi:10.1038/s42004-023-00894-6
- Park, 2022, A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer, BMC Cancer, 22, 28, 10.1186/s12885-021-09138-z · doi:10.1186/s12885-021-09138-z
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Gouez, M., Pérol, O., Pialoux, V., Avrillon, V., Boussageon, M., Decroisette, C., Delrieu, L., El Hajj, H., Fournier, B., Gille, R., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15010334 · Cited by 3
“ICPi efficacy depends on effective antitumor immune response, including adequate immune system competence, tumor infiltration by T lymphocytes, recognition of tumor-specific antigens, and a permissive tumor microenvironment [6,7].”
Metadata
- Authors
- Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2024-11
- Volume
- 42
- Issue
- 11
- Pages
- 1825-1863
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4403299725
- Cited by
- 565
- References
- 443
- FWCI
- 86.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- American-Italian Cancer Foundation (223565-01)
- National Cancer Institute (CA271915)
- Leukemia and Lymphoma Society
- Associazione Italiana per la Ricerca sul Cancro (IG 2022 27685)
- National Institutes of Health
- Stand Up To Cancer
- Weill Cornell Medicine
- Luke Heller Tec Pr2 Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.